Decoy and antisense RNA oligonucleotides targeting the EGFR exon 3 splice site suppress proliferation of A172 glioblastoma cells

Two antisense and two decoy 2’-modified RNA oligonucleotides targeting the EGFR exon 3 3’ splice site region suppress proliferation of A172 glioblastoma cells.

• Why it matters: EGFR exon definition depends on RNA-binding proteins near splice sites, and glioblastoma growth is linked to RNA-binding activity, creating a need for splice-site–targeted RNA therapeutics.
• What they did: Using SpliceAid to prioritize YB-1 (YBX1) near the exon 3 3’ splice site, the study tested four oligonucleotides (asRNA1, asRNA2, dRNA2, dYB-1) in A172 and A549 cells, with Western blot, RT-PCR, immunocytochemistry, and proliferation measured days 1–3.
• The result: In A172 cells, all four reduced EGFR protein in a single Western blot and asRNA1, asRNA2, and dRNA2 reduced proliferation versus scrambled RNA at days 1–3, while dYB-1 matched the reduction at day 3; no detectable effects occurred in A549 cells.